Omics Landscape in Disease Biomarkers Discovery
Total Page：16
File Type：pdf, Size：1020Kb
Disease Markers Omics Landscape in Disease Biomarkers Discovery Guest Editors: Monica Neagu, Caterina Longo, and Simone Ribero Omics Landscape in Disease Biomarkers Discovery Disease Markers Omics Landscape in Disease Biomarkers Discovery Guest Editors: Monica Neagu, Caterina Longo, and Simone Ribero Copyright © 2016 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Disease Markers.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Silvia Angeletti, Italy Yi-Chia Huang, Taiwan Esperanza Ortega, Spain Elena Anghileri, Italy Chao Hung Hung, Taiwan Roberta Palla, Italy Paul Ashwood, USA Sunil Hwang, USA Sheng Pan, USA Fabrizia Bamonti, Italy Grant Izmirlian, USA MarcoE.M.Peluso,Italy Bharati V. Bapat, Canada Yoshio Kodera, Japan Robert Pichler, Austria Valeria Barresi, Italy Chih-Hung Ku, Taiwan Alex J. Rai, USA Jasmin Bektic, Austria Dinesh Kumbhare, Canada Irene Rebelo, Portugal Riyad Bendardaf, Finland Mark M. Kushnir, USA Andrea Remo, Italy L. Bocchio-Chiavetto, Italy Taina K. Lajunen, Finland Gad Rennert, Israel Donald H. Chace, USA Olav Lapaire, Switzerland Manfredi Rizzo, Italy Kishore Chaudhry, India Claudio Letizia, Italy Iwona Rudkowska, Canada Carlo Chiarla, Italy Xiaohong Li, USA Maddalena Ruggieri, Italy M. M. Corsi Romanelli, Italy Ralf Lichtinghagen, Germany Vincent Sapin, France Benoit Dugue, France Lance A. Liotta, USA Tori L. Schaefer, USA Helge Frieling, Germany Leigh A. Madden, UK Anja Hviid Simonsen, Denmark Paola Gazzaniga, Italy Michele Malaguarnera, Italy Eric A. Singer, USA Giorgio Ghigliotti, Italy Heidi M. Malm, USA Holly Soares, USA Matteo Giulietti, Italy Upender Manne, USA Tomás Sobrino, Spain Alvaro González, Spain Ferdinando Mannello, Italy Claudia Stefanutti, Italy Mariann Harangi, Hungary Serge Masson, Italy M. Mayke Streppel, Netherlands Michael Hawkes, Canada Maria Chiara Mimmi, Italy Michael Tekle, Sweden Andreas Hillenbrand, Germany Ross Molinaro, USA Stamatios E. Theocharis, Greece Hubertus Himmerich, UK Giuseppe Murdaca, Italy Tilman Todenhöfer, Germany Johannes Honekopp, UK Szilárd Nemes, Sweden Natacha Turck, Switzerland Shih-Ping Hsu, Taiwan Dennis W.T. Nilsen, Norway Heather Wright Beatty, Canada Contents Omics Landscape in Disease Biomarkers Discovery Monica Neagu, Caterina Longo, and Simone Ribero Volume 2016, Article ID 4068252, 2 pages Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma Alexandra Ion, Iris Maria Popa, Laura Maria Lucia Papagheorghe, Cristina Lisievici, Mihai Lupu, Vlad Voiculescu, Constantin Caruntu, and Daniel Boda Volume 2016, Article ID 9602472, 8 pages Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease Simona Mihai, Elena Codrici, Ionela Daniela Popescu, Ana-Maria Enciu, Elena Rusu, Diana Zilisteanu, Radu Albulescu, Gabriela Anton, and Cristiana Tanase Volume 2016, Article ID 3185232, 11 pages CEACAM1: Expression and Role in Melanocyte Transformation Gabriela Turcu, Roxana Ioana Nedelcu, Daniela Adriana Ion, Alice Brînzea, Mirela Daniela Cioplea, Lucia Beatrice Jilaveanu, and Sabina Andrada Zurac Volume 2016, Article ID 9406319, 8 pages From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers Vlad Voiculescu, Bogdan Calenic, Mihaela Ghita, Mihai Lupu, Ana Caruntu, Liliana Moraru, Suzana Voiculescu, Alexandra Ion, Maria Greabu, Nikolay Ishkitiev, and Constantin Caruntu Volume 2016, Article ID 4517492, 14 pages Gene Expression and Proteome Analysis as Sources of Biomarkers in Basal Cell Carcinoma Mihai Lupu, Constantin Caruntu, Mihaela Adriana Ghita, Vlad Voiculescu, Suzana Voiculescu, Adrian E. Rosca, Ana Caruntu, Liliana Moraru, Iris Maria Popa, Bogdan Calenic, Maria Greabu, and Daniela Elena Costea Volume 2016, Article ID 9831237, 9 pages Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis Cristiana Popp, Luciana Nichita, Theodor Voiosu, Alexandra Bastian, Mirela Cioplea, Gianina Micu, Gabriel Pop, Liana Sticlaru, Andreea Bengus, Andrei Voiosu, and Radu Bogdan Mateescu Volume 2016, Article ID 3625279, 7 pages Inflammatory Biomarkers Profile as Microenvironmental Expression in Keratoconus Catalina Ionescu, Catalina Gabriela Corbu, Cristiana Tanase, Christian Jonescu-Cuypers, Cristina Nicula, Dana Dascalescu, Miruna Cristea, and Liliana-Mary Voinea Volume 2016, Article ID 1243819, 8 pages Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications A. Quintanal-Villalonga, Luis Paz-Ares, Irene Ferrer, and S. Molina-Pinelo Volume 2016, Article ID 9214056, 14 pages Circulating MicroRNAs as Potential Molecular Biomarkers in Pathophysiological Evolution of Pregnancy Dragos Cretoiu, Jiahong Xu, Junjie Xiao, Nicolae Suciu, and Sanda Maria Cretoiu Volume 2016, Article ID 3851054, 7 pages Discovery and Validation of Hypermethylated Markers for Colorectal Cancer Jiufeng Wei, Guodong Li, Shuwei Dang, Yuhui Zhou, Kai Zeng, and Ming Liu Volume 2016, Article ID 2192853, 7 pages Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer Ángela Marrugal, Laura Ojeda, Luis Paz-Ares, Sonia Molina-Pinelo, and Irene Ferrer Volume 2016, Article ID 2138627, 12 pages Hindawi Publishing Corporation Disease Markers Volume 2016, Article ID 4068252, 2 pages http://dx.doi.org/10.1155/2016/4068252 Editorial Omics Landscape in Disease Biomarkers Discovery Monica Neagu,1,2 Caterina Longo,3 and Simone Ribero4 1 Victor Babes National Institute of Pathology, Bucharest, Romania 2Faculty of Biology, University of Bucharest, Bucharest, Romania 3Skin Cancer Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy 4University of Turin, Turin, Italy Correspondence should be addressed to Monica Neagu; [email protected] Received 22 September 2016; Accepted 22 September 2016 Copyright © 2016 Monica Neagu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Biomarkerdiscoveryhasanacceleratedpaceistakingadvan- Hencefromthelargegroupofskincancerspapers,M. tage of ever growing omics technologies. In the last years Lupu et al. review the genomic and the proteomic profile we are facing the development of a myriad of technologies of basal cell carcinoma, the world’s leading skin cancer. searching for the “golden biomarker.” The omics family The paper analyzes the gene expression and proteomic is constantly adding a new member, such as genomics, profiling of both tumor cells and tumoral microenvironment. proteomics, peptidomics, newer ones, epigenomics, tran- These patterns can represent novel predictive and prognostic scriptomics, metabolomics, lipidomics, pharmacogenomics, biomarkers in BCC. interactomics, and chronemics, just mentioning a few [1]. The second most frequent skin cancer squamous cells car- In the biomarker development, approaches are multidis- cinoma is reviewed by V.Voiculescu et al. where environmen- ciplinary, from basic to translational and clinical research. As tal factor ultraviolet light, chronic scarring/inflammation, biological processes are complex, for example, tumorigenesis, exposure to chemical compounds, and immune suppression multitechnological approaches are crucial for protein/gene can favour tumorigenesis. The paper shows that malig- biomarkers discovery. Biomarker discovery goes through nant keratinocyte proteome analysis is the pool for novel laborious individual phases, such as biomarker candidate biomarker discovery future to be used in early detection, risk identification, verification, and validation. In all these phases, assessment, tumor monitoring, and development of targeted various omics technologies take the lead. Depending on therapeutic strategies. the development stage, when characterizing thousands to Another skin related paper focuses on melanoma devel- tens of thousands of proteins, the key technological play- opmentandG.Turcuetal.revisedaninterestingnewpossible ers are mass spectrometry, multiplexed assays, and protein biomarker, carcinoembryonic antigen cell adhesion molecule microarrays. For genomic studies, technological platforms 1 (CEACAM1) with a definite role in melanoma metastasis. of gene microarrays, next-generation sequencing, and mass Knowing that melanoma progression is associated with cell spectrometry generate tumor-associated genes and potential adhesion molecules dysregulation, this molecule can further biomarkers. Complementary omics approaches intended for stratify high risk patients identifying subgroups that require biomarker candidates selection should focus on multiple close follow-up or more aggressive therapy. proteomic/genomic/metabolomic targets. These multifaceted Lungcancerwasapproachedintwopapersofthis targets could better explain complex disease mechanisms [2]. special issue. A. Quintanal-Villalonga et al. reviewed tyrosine The special issue is governed by three tumor patholo- kinase receptor with its therapeutical implications in lung gies, skin cancer, lung cancer, and colorectal cancer, while cancer showing that in the “omics” landscape tyrosine kinase precancerous lesions like ulcerative colitis or particular receptors gained their role in the different histological types inflammatory conditions like keratoconus, kidney disease, or of lung cancer. This receptor